SFE Investment Counsel Buys 3,812 Shares of Pfizer Inc. $PFE

SFE Investment Counsel increased its position in Pfizer Inc. (NYSE:PFE) by 5.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 75,230 shares of the biopharmaceutical company’s stock after purchasing an additional 3,812 shares during the quarter. SFE Investment Counsel’s holdings in Pfizer were worth $1,824,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Zions Bancorporation National Association UT raised its holdings in shares of Pfizer by 25.3% in the second quarter. Zions Bancorporation National Association UT now owns 344,625 shares of the biopharmaceutical company’s stock valued at $8,354,000 after acquiring an additional 69,497 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC increased its position in Pfizer by 1.1% during the 2nd quarter. Pinnacle Wealth Management Advisory Group LLC now owns 66,284 shares of the biopharmaceutical company’s stock valued at $1,607,000 after purchasing an additional 693 shares during the period. Summit Asset Management LLC increased its position in Pfizer by 3.6% during the 2nd quarter. Summit Asset Management LLC now owns 24,115 shares of the biopharmaceutical company’s stock valued at $585,000 after purchasing an additional 848 shares during the period. Midwest Trust Co bought a new stake in shares of Pfizer in the 2nd quarter valued at about $5,634,000. Finally, FDx Advisors Inc. lifted its position in shares of Pfizer by 15.3% in the 2nd quarter. FDx Advisors Inc. now owns 10,707 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 1,419 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.45 on Friday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The company has a market cap of $138.99 billion, a PE ratio of 13.00, a P/E/G ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The business has a 50-day simple moving average of $24.74 and a two-hundred day simple moving average of $24.37.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is presently 100.00%.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Bank of America lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday. UBS Group reiterated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Citigroup increased their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.18.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.